抑制HDAC1-IRF4轴和PIM激酶的新型抗骨髓瘤治疗选择
本研究探讨组氨酸去乙酰化酶1(HDAC1)在多发性骨髓瘤(MM)细胞中对转录因子IRF4和促生存介质PIM2激酶组成性激活的作用。用I类HDAC抑制剂MS-275敲低或抑制HDAC1可降低MM细胞中IRF4和PIM2的基础表达。机制上,抑制HDAC1通过组蛋白超乙酰化和抑制RNA聚合酶II在IRF4位点的募集来降低IRF4转录,从而减少包括PIM2在内的IRF4靶基因。除HDAC1-IRF4轴对PIM2的转录调控外,骨髓基质细胞和白细胞介素-6(IL-6)的外部刺激可显著上调PIM2,上调的PIM2有助于减弱MS-275的细胞毒性作用。在IL-6存在下及体内,I类HDAC和PIM激酶抑制剂协同抑制MM细胞生长。因此,本研究结果表明,同时靶向内在HDAC1-IRF4轴和外部激活的PIM2是治疗骨髓中生长的MM的有效治疗选择。
要点
- 抑制HDAC1可降低MM细胞中IRF4和PIM2的基础表达。
- 骨髓基质细胞和IL-6可上调PIM2,减弱MS-275的细胞毒性。
- I类HDAC和PIM激酶抑制剂在IL-6存在下及体内协同抑制MM细胞生长。
核心结论
- 同时靶向内在HDAC1-IRF4轴和外部激活的PIM2是治疗骨髓中生长的MM的有效治疗选择。
研究设计与样本
- 研究探讨HDAC1在MM细胞中对IRF4和PIM2组成性激活的作用,使用I类HDAC抑制剂MS-275敲低或抑制HDAC1。
主要发现
- 敲低或抑制HDAC1可降低MM细胞中IRF4和PIM2的基础表达。
- 抑制HDAC1通过组蛋白超乙酰化和抑制RNA聚合酶II在IRF4位点的募集来降低IRF4转录,减少包括PIM2在内的IRF4靶基因。
- 骨髓基质细胞和IL-6的外部刺激可显著上调PIM2,上调的PIM2有助于减弱MS-275的细胞毒性作用。
- 在IL-6存在下及体内,I类HDAC和PIM激酶抑制剂协同抑制MM细胞生长。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the prosurvival mediator PIM2 kinase in MM cells. The knockdown or inhibition of HDAC1 by the class I HDAC inhibitor MS-275 reduced the basal expression of IRF4 and PIM2 in MM cells. Mechanistically, the inhibition of HDAC1 decreased IRF4 transcription through histone hyperacetylation and inhibiting the recruitment of RNA polymerase II at the IRF4 locus, thereby reducing IRF4-targeting genes, including PIM2. In addition to the transcriptional regulation of PIM2 by the HDAC1-IRF4 axis, PIM2 was markedly upregulated by external stimuli from BM stromal cells and interleukin-6 (IL-6). Upregulated PIM2 contributed to the attenuation of the cytotoxic effects of MS-275. Class I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in the BM.
引用
- Harada T, Ohguchi H, Oda A, et al. Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase. Blood Adv. 2023. PMID: 36129197. doi:10.1182/bloodadvances.2022007155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。